Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.53 +3.09%

+$0.08 today

Market cap
$297.72M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.25M

Average 3.81M

Returns on capital

Altimmune, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-39.2%

avg 43.3%

ROIC

-35.4%

avg -49.7%

ROA

-31.5%

avg -32.8%

Analysis

ROA is currently the strongest return metric at -31.5% versus its period average of -32.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Scot Roberts

Chief Scientific OfficerUSD 683.23K67——

Gregory L. Weaver

Chief Financial OfficerUSD 619.69K7073.00K0.08%

Raymond Jordt

Chief Business OfficerUSD 578.85K53——

Christophe Arbet-Engels

Chief Medical OfficerUSD 361.36K6324.82K0.03%

Jerome Benedict Durso

Chairman, CEO & PresidentUSD 50.94K5893.20K0.11%

Luis Sanay

Vice President of Investor Relations————

Richard Menziuso

VP, Global Controller & Principal Accounting Officer—51——

Tony Blandin

Vice President of Quality & Compliance Management————

Andrew Shutterly

Principal Financial & Accounting Officer and Corporate Controller—3811.37K0.01%

Bertrand Georges

Chief Technology Officer————

Robin E. Abrams

Chief Legal Officer & Corporate Secretary—62——

Linda Richardson

Chief Commercial Officer—62——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 13, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

14

$452,281.91

Sells

0

$0.00

Net Transaction Value

+$452,281.91

Net buying

Most Active

Durso Jerome Benedict

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 13, 26

Durso Jerome Benedict

Direct

Buy$49.7K
Nov 13, 26

WEAVER GREGORY L

Direct

Buy$16.2K
Nov 13, 26

Pisano Wayne

Direct

Buy$16.4K
Aug 13, 26

Durso Jerome Benedict

Direct

Buy$44.3K
Apr 6, 26

GILL JOHN

Direct

Buy$31.3K
Apr 1, 26

WEAVER GREGORY L

Direct

Buy$31.5K
Apr 1, 26

Durso Jerome Benedict

Direct

Buy$47.1K
Mar 6, 26

WEAVER GREGORY L

Direct

Buy$17.7K
Mar 6, 26

Durso Jerome Benedict

Direct

Buy$70.8K
Jan 8, 26

Pisano Wayne

Direct

Buy$20.4K

1–10 of 14

Summary

Insiders reported 14 buys worth $452,281.91 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $452,281.91. Durso Jerome Benedict was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
+418.3% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +418.3% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Altimmune, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ALT's management, answered from reported figures.

Who manages ALT?

Altimmune, Inc. (ALT) lists 12 active executives. The top listed executive is Jerome Benedict Durso, Chairman, CEO & President.

Are ALT insiders buying or selling?

Recent insider activity shows net buying of $29.21M.